Glenmark introduces DCGI-approved type-2 diabetes drug in India
Category: #health  By Pankaj Singh   Date: 2022-04-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Glenmark introduces DCGI-approved type-2 diabetes drug in India

Indian pharmaceutical company, Glenmark has reportedly introduced a new FDC (fixed-dose combination) of a broadly used Dipeptidyl Peptidase 4 (DPP4) inhibitor, Teneligliptin, with Pioglitazone for people who have type 2 diabetes.

The drug, which is launched under the Zita Plus Pio brand name, will increase the availability of the quality drug for managing diabetes.

Currently, Zita Plus Pio is the only available combination of Glitazone and DPP4 brands in India.

The FDC of Pioglitazone+Teneligliptin is approved by the Drug Controller General of India (DCGI) and will aid in advancing the glycemic control in the adult population with insulin struggle, those whose diabetes is unable to be controlled by metformin, and those who need the addition of Pioglitazone and Teneliglitptin as different drugs.

Glenmark Pharmaceuticals’ Head and Group VP – India Formulations, Alok Malik, while commenting on the development, said that diabetes is a major area of focus for Glenmark, a leader in offering novel options of treatment for diabetic patients in India.

The firm is delighted to unveil this novel Zita Plus Pio, which is said to be the very first kind of drug available in the country, offering an affordable and top-class option for treating adult diabetic patients.

According to the IDF (International Diabetes Federation), the pervasiveness of diabetes in India is about 75 million adults, which is estimated to rise to 125 million (around 70% increase) by 2045. Of these, around 77% of patients have uncontrolled diabetes.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a pharmaceutical company that has spread its global presence across generics, specialty, and OTC businesses. It emphasizes the major therapeutic areas of dermatology, respiratory, and oncology.

Recently, the drug maker combined net profit dropped 3.4% to Rs 239.75 crore on a 13.9% increase in net sales to Rs 3,141.47 crore in Q3 FY22 compared to Q3 FY21. Its stock also fell 1.52% to Rs 436.70 on the BSE.

Source Credit - https://www.business-standard.com/article/news-cm/glenmark-pharma-launches-fdc-for-type-2-diabetes-in-india-122042500220_1.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

...

Read More

More News By Pankaj Singh

Hamilton Lane widens Southeast Asia footprint, expands into Singapore
Hamilton Lane widens Southeast Asia footprint, expands into Singapore
By Pankaj Singh

Renowned private markets fund management company, Hamilton Lane, has reportedly announced that it has increased its presence across Singapore by appointing Kerrine Koh to lead the company’s office in the region, teaming up with Singaporean...

New Zealand withdraws most COVID restrictions as cases decline
New Zealand withdraws most COVID restrictions as cases decline
By Pankaj Singh

New Zealand reportedly removed most of its remaining COVID-19 restrictions with the government signaling a return to the pre-pandemic era. As reported, people will not have to wear masks in stores, buses, planes, and supermarkets. The remaining ma...

Syniti partners with TD SYNNEX to facilitate robust data solutions
Syniti partners with TD SYNNEX to facilitate robust data solutions
By Pankaj Singh

Syniti, a global data management enterprise, has reportedly announced joining forces with IT solution aggregator TD SYNNEX, a product of the merger of Synnex Corporation and Tech Data Corporation. This collaboration will provide businesses priorit...